Welcome to our dedicated page for CINC news (Ticker: CINC), a resource for investors and traders seeking the latest updates and insights on CINC stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CINC's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CINC's position in the market.
CinCor Pharma has initiated its Phase 2 clinical trial, figHTN-CKD, assessing the efficacy of baxdrostat (CIN-107) in patients experiencing uncontrolled hypertension and chronic kidney disease (CKD). The trial aims to enroll 300 patients, with results expected in the second half of 2023. This study is crucial as CKD affects over 37 million individuals in the U.S. Current treatments may lead to aldosterone breakthrough, highlighting the potential significance of baxdrostat's unique mechanism. The primary endpoint is the change in systolic blood pressure after 26 weeks of treatment.
CinCor Pharma announced its participation in the Jefferies 2022 Healthcare Conference, scheduled for June 8-10 in New York. The management team will present on June 9 at 9 AM EDT, with a live webcast available online. A replay of the presentation will be archived for 90 days. CinCor, a clinical-stage biopharmaceutical company founded in 2018, focuses on innovative treatments for cardio-renal diseases, with its lead asset, baxdrostat (CIN-107), in development for hypertension and primary aldosteronism.
CinCor Pharma today announced participation in two upcoming conferences: the H.C. Wainwright 2022 Global Investment Conference from May 23-26 and the UBS 2022 Global Healthcare Conference from May 23-25. The H.C. Wainwright presentation will be available on-demand starting May 24 at 7 AM EST, while the UBS live presentation is set for May 24 at 7:45 AM EST. CinCor, a clinical-stage biopharmaceutical firm founded in 2018, focuses on innovative treatments for cardio-renal diseases, with its lead asset, baxdrostat (CIN-107), targeting hypertension and primary aldosteronism.
CinCor Pharma reported strong financial performance in Q1 2022, raising $194 million in its IPO, extending its cash runway into 2024. The company has completed enrollment of its BrigHtn Phase 2 trial for treatment-resistant hypertension, with topline data expected in 2H 2022. R&D expenses rose to $9.7 million, reflecting ongoing clinical trials, while G&A expenses decreased to $4.0 million. The net loss for Q1 2022 was $16.7 million, up from $5.6 million a year earlier. Cash position stood at $314.2 million as of March 31, 2022, indicating a robust liquidity position.
CinCor Pharma announced its participation in the Jefferies Biotech on the Bay Summit on April 26-27, 2022, in Miami, Florida. The management will hold one-on-one investor meetings, and interested investors should reach out to their Jefferies representatives.
Founded in 2018, CinCor is a clinical-stage biopharmaceutical company focused on treating cardio-renal diseases. Its lead product, CIN-107, is an oral small molecule inhibitor targeting aldosterone synthase, aimed at combating hypertension and primary aldosteronism in patients with significant unmet needs.
CinCor Pharma reported a significant year, completing its BrigHtn Phase 2 trial enrollment with 275 patients and advancing multiple studies for its lead product, CIN-107, aimed at treating hypertension. The company successfully raised $141.9 million through a Series B financing and $193.2 million from its IPO, strengthening its cash position to approximately $336 million. Despite a net loss of $50.4 million in 2021, the company expressed optimism about its clinical progress and cash runway supporting operations through 2024. Topline data from ongoing trials is expected in late 2022.
CinCor Pharma, a clinical-stage biopharmaceutical firm, will join the Russell 2000 and Russell 3000 Indexes effective March 18, 2022. This inclusion follows a successful IPO in January 2022, aimed at enhancing visibility among investors. The Russell 2000 measures small-cap performance and represents about 10% of the Russell 3000's market cap, with $10.7 trillion in assets benchmarked against these indexes. CinCor focuses on developing CIN-107 for hypertension and cardio-renal diseases, with significant market potential as hypertension affects approximately 20% of the global population.
CinCor Pharma, Inc. (NASDAQ: CINC) will report its fourth quarter and full year 2021 financial results before the U.S. markets open on March 22, 2022. A conference call will occur at 8:30 AM Eastern Time to discuss the outcomes and business updates.
CinCor specializes in developing CIN-107, a selective oral inhibitor targeting aldosterone synthase for hypertension and other cardio-renal diseases. The live conference call can be accessed through the company’s website with a replay available for 30 days post-call.
BOSTON, March 03, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, a clinical-stage biopharmaceutical company, announced its participation in the 32nd Annual Oppenheimer Healthcare Conference from March 15-17, 2022. The management team will present on March 16, 2022, at 10 am EST. CinCor focuses on developing CIN-107, an oral small molecule inhibitor of aldosterone synthase, to treat hypertension and cardio-renal diseases. Investors can contact Oppenheimer & Co. for meeting arrangements during the conference.
CinCor Pharma announced the appointment of June Lee, M.D., to its Board of Directors, enhancing its leadership as it advances clinical programs. Dr. Lee, a seasoned industry expert, aims to guide the development of CIN-107, a selective aldosterone synthase inhibitor targeting hypertension and renal diseases. This strategic move follows CinCor’s successful IPO and ongoing Phase 2 trials of CIN-107. Dr. Lee's extensive experience in drug development and leadership is expected to bolster CinCor’s innovative efforts in treating cardio-renal diseases with significant unmet needs.
